Early Experience With Neovasc’s Mitral Valve Is Encouraging; Edwards’ Disappoints
This article was originally published in The Gray Sheet
Physicians attending the EuroPCR conference in Paris heard presentations of first-in-man case studies on two new transcatheter mitral valve replacement technologies, one from Neovasc, and one from Edwards Lifesciences.
You may also be interested in...
Neovasc Inc. is targeting two highly underserved markets in cardiology – refractory angina and mitral valve disease – with unique transcatheter solutions. The angina device, called the Neovasc Reducer, is expected to enter the European market early next year.
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.
'Hunker Down, Expect The Worst And Hope For The Best:' Investment Analyst Advises Medtech Businesses To Cut Costs
Maxim Jacobs, managing partner at Edison Investment Research urges medtech companies to be financially prudent as the COVID-19 pandemic worsens. Cancellations of routine surgeries are creating a huge strain on device businesses which could continue for months.